Last reviewed · How we verify

SONIDEGIB — Competitive Intelligence Brief

SONIDEGIB (SONIDEGIB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

marketed Smoothened Small molecule Live · refreshed every 30 min

Target snapshot

SONIDEGIB (SONIDEGIB). Sonidegib inhibits the Hh pathway by binding to and blocking Smoothened, a key transmembrane protein.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
SONIDEGIB TARGET SONIDEGIB marketed Smoothened 2015-01-01
Daurismo glasdegib Pfizer marketed Hedgehog Pathway Inhibitor [EPC] Smoothened homolog 2018-01-01
Daurismo Glasdegib Maleate Pfizer marketed Hedgehog pathway inhibitor Smoothened (transmembrane protein) 2018-01-01
Erivedge vismodegib Roche marketed Hedgehog Pathway Inhibitor [EPC] Smoothened 2012-01-01
Sonidegib Phosphate Capsules Sonidegib Phosphate Capsules Jemincare marketed Hedgehog pathway inhibitor Smoothened (SMO)
ERIVEDGE ERIVEDGE University Hospital, Lille marketed Hedgehog pathway inhibitor Smoothened (SMO)
Treatment with vismodegib Treatment with vismodegib University Hospital, Bordeaux marketed Hedgehog pathway inhibitor Smoothened (SMO)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SONIDEGIB — Competitive Intelligence Brief. https://druglandscape.com/ci/sonidegib. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: